| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
41,610,000 |
| Market
Cap: |
83.22(M) |
| Last
Volume: |
1,136,985 |
Avg
Vol: |
1,133,856 |
| 52
Week Range: |
$0.900001 - $2.955 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Media |
| Level
III Sector: |
Broadcasting - TV |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Brooklyn ImmunoTherapeutics is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Co. is seeking to develop IRX-2, a cytokine-based therapy, to treat patients with cancer. Co. also is exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using gene-editing and cell therapy technology through a license with Factor Bioscience Limited and through its subsidairies, Novellus, Inc. and Novellus, Ltd.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
880,962 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,889,556 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Monovoukas Yiannis |
|
– • – |
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,681,359 |
|
- |
|
| Gurrola Sandra M |
Former SVP of Finance |
• • – |
2021-03-24 |
4 |
D |
$2.67 |
$16,271 |
D/D |
(6,094) |
21,617 |
|
- |
|
| Wolff Allen |
Former Director and CEO |
• • – |
2021-03-24 |
4 |
D |
$2.67 |
$26,550 |
D/D |
(9,944) |
128,520 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2021-03-19 |
4 |
D |
$3.53 |
$731 |
D/D |
(207) |
138,464 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2021-03-19 |
4 |
D |
$3.53 |
$409 |
D/D |
(116) |
27,711 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2021-02-19 |
4 |
D |
$4.81 |
$553 |
D/D |
(115) |
27,827 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2021-02-19 |
4 |
D |
$4.81 |
$996 |
D/D |
(207) |
138,671 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2021-01-19 |
4 |
D |
$2.55 |
$3,570 |
D/D |
(1,400) |
27,942 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2021-01-19 |
4 |
D |
$2.55 |
$7,617 |
D/D |
(2,987) |
138,878 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2020-12-19 |
4 |
D |
$2.17 |
$369 |
D/D |
(170) |
141,865 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2020-12-19 |
4 |
D |
$2.17 |
$217 |
D/D |
(100) |
29,342 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2020-11-20 |
4 |
D |
$1.88 |
$184 |
D/D |
(98) |
29,442 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2020-11-20 |
4 |
D |
$1.88 |
$320 |
D/D |
(170) |
142,035 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2020-10-21 |
4 |
D |
$2.05 |
$2,415 |
D/D |
(1,178) |
29,540 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2020-10-21 |
4 |
D |
$2.05 |
$5,029 |
D/D |
(2,453) |
142,205 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2020-09-22 |
4 |
D |
$1.99 |
$193 |
D/D |
(97) |
30,718 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2020-09-22 |
4 |
D |
$1.99 |
$338 |
D/D |
(170) |
144,658 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2020-08-25 |
4 |
D |
$2.62 |
$257 |
D/D |
(98) |
30,815 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2020-08-25 |
4 |
D |
$2.62 |
$445 |
D/D |
(170) |
144,828 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2020-08-13 |
4 |
S |
$5.33 |
$910,060 |
I/I |
(170,900) |
16,194 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2020-08-13 |
4 |
S |
$5.79 |
$906,908 |
D/D |
(156,750) |
421 |
|
- |
|
| Wolff Allen |
CEO |
• • – |
2020-07-28 |
4 |
D |
$1.85 |
$4,538 |
D/D |
(2,453) |
144,998 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2020-07-28 |
4 |
D |
$1.85 |
$2,179 |
D/D |
(1,178) |
30,913 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2020-06-17 |
4 |
S |
$6.01 |
$74,524 |
I/I |
(12,400) |
187,094 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2020-06-16 |
4 |
S |
$3.86 |
$386 |
I/I |
(100) |
199,494 |
|
- |
|
232 Records found
|
|
Page 2 of 10 |
|
|
0.03 (1.48%) 
